DoJ takes PLATO off its plate

The U.S. Department of Justice (DoJ) closed its investigation into the pivotal PLATO trial and will take no further action, according the drug maker AstraZeneca.

In 2013, the civil division of the DoJ requested that AstraZeneca provide access to documents and information about PLATO (PLatelet Inhibition And paTient Outcomes). PLATO showed that ticagrelor (Brilinta) significantly reduced the rate of death from vascular causes, MI or stroke without an increase in the rate of overall major bleeding compared with clopidogrel (Plavix, Bristol-Myers Squibb) in patients with acute coronary syndrome.

Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that received FDA approval in 2011 based on the results of PLATO. The FDA postponed its decision several times before approving the antiplatelet treatment for patients with acute coronary syndrome.

AstraZeneca announced that it is proceeding with several other trials, including SOCRATES, which will evaluate ticagrelor in patients with acute ischemic stroke or transient ischemic attack; EUCLID, for patients with peripheral artery disease; and PEGASUS, as secondary prevention in patients with a previous MI.

Candace Stuart, Contributor

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.